Company Description
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States.
The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models.
It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors.
The company was incorporated in 2016 is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 92 |
| CEO | Eli Wallace |
Contact Details
Address: 256 East Grand Avenue, Suite 104 South San Francisco, California 94080 United States | |
| Phone | 650 405 4770 |
| Website | bbotx.com |
Stock Details
| Ticker Symbol | BBOT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001869105 |
| ISIN Number | US1079241022 |
Key Executives
| Name | Position |
|---|---|
| Eli M. Wallace Ph.D. | Chief Executive Officer and Director |
| Dr. Pedro J. Beltran M.D., Ph.D. | Chief Scientific Officer |
| Dr. Yong Ben M.B.A., M.D. | Chief Medical and Development Officer |
| Uneek Mehra M.B.A. | Chief Financial Officer |
| Howard Y. Chang M.D., Ph.D. | Vice President of Operations |
| Aaron Chan J.D. | Vice President of Legal |
| Angela Peters | Senior Vice President of People |
| Idan Elmelech M.A., M.B.A. | Senior Vice President of Strategy and Business Development |
| Bin Wang Ph.D. | Senior Vice President of Drug Discovery |
| Daniel Watson Ph.D. | Senior Vice President of Chemistry, Manufacturing and Controls |